Navigation Links
Gut hormone test predicts individual efficacy of gastric bypass
Date:11/8/2013

The gastric bypass is one of the most commonly performed surgical procedures in the treatment of obesity. In most patients, it quickly produces substantial body weight loss. Moreover, even before the weight loss, the procedure leads to improved glucose tolerance. However, these metabolic improvements vary considerably from patient to patient.

A hormone test may be able to predict the extent of metabolic improvement caused by the gastric bypass. These are the results of a study on a rodent model conducted by Prof. Dr. Matthias Tschp and his colleagues from the Institute of Diabetes and Obesity (IDO), Helmholtz Diabetes Center at Helmholtz Zentrum Mnchen together with a team of researchers led by Dr. Kirk Habegger at the Metabolic Disease Institute of the University of Cincinnati.

After gastric bypass surgery, the concentration of the gut hormone GLP-1 (glucagon-like peptide 1) in the blood rises significantly. GLP-1 increases insulin secretion and contributes to improved blood glucose levels and blood lipids. As the rat studies by the Tschp and Habegger research teams showed, GLP-1 responsiveness varied considerably with regard to glucose metabolism. More importantly, the more responsive the animals were to GLP-1, the greater the efficacy of the gastric bypass turned out to be regarding glucose metabolism improvements.

Thus, the responsiveness to GLP-1 could be a key indicator for the success of the gastric bypass. "If our results are confirmed in clinical trials with patients, the hormone response could be tested before the planned surgery and surgeons would be able to predict how much an individual patient's glucose metabolism would benefit," said Tschp. "This will contribute to the development of personalized therapies for type 2 diabetes and obesity. For surgical procedures such as gastric bypass this is particularly compelling because such operations are complex and cannot be easily reversed."

The numerous secondary diseases related to excess weight and obesity, such as type 2 diabetes, are among the most common diseases in Germany. These diseases are the focus of research at Helmholtz Zentrum Mnchen, a partner in the German Center for Diabetes Research (DZD).


'/>"/>

Contact: Matthias Tschöp
matthias.tschoep@helmholtz-muenchen.de
49-893-187-2103
Helmholtz Zentrum Mnchen - German Research Center for Environmental Health
Source:Eurekalert

Related biology news :

1. BRG1 mutations confer resistance to hormones in lung cancer
2. Estrogen hormone reveals protective ability after traumatic brain injury
3. Measuring progesterone receptor expression to improve hormone-receptor-positive cancer management
4. Hormones dictate when youngsters fly the nest, says new research
5. Hormone-mimicking chemicals cause inter-species mating
6. Lighting up the plant hormone command system
7. Hormone in fruit flies sheds light on diabetes cure, weight-loss drug for humans
8. Stress hormones: Good or bad for posttraumatic stress disorder risk?
9. New cause of thyroid hormone deficiency discovered
10. Hormone combination effective and safe for treating obesity in mice
11. Estrogenic plants linked to altered hormones, possible behavior changes in monkeys
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2020)... N.J. (PRWEB) , ... July 01, 2020 , ... ... announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in ... the company’s existing Japanese clinical supply facility located in Kakegawa, the new 60,000-square-foot ...
(Date:6/28/2020)... (PRWEB) , ... June 25, 2020 , ... In an ... on innovations in accelerated Point of Care Testing solutions (POCT). Check local listings for ... are collected at medical offices and are shipped to labs throughout the country. Results ...
(Date:6/23/2020)... ... June 23, 2020 , ... First Aid Africa, a ... UK supplier and manufacturer of innovative portable renewable energy equipment, have announced the ... against the COVID-19 pandemic in Zambia. , One of Renovagen’s FAST FOLD portable ...
Breaking Biology News(10 mins):
(Date:7/1/2020)... ... June 30, 2020 , ... ... the launch of a new clinical diagnostics immuno-oncology service, TissueInsight . ... (TME). , “Flagship’s TissueInsight is a service that aids pathologists, oncologists, and ...
(Date:6/28/2020)... ... June 25, 2020 , ... Lumeda Inc. (“Lumeda”), ... announced the company has entered a license agreement with Roswell Park Comprehensive Cancer ... exclusive rights to Roswell Park intellectual property surrounding a novel medical device and ...
(Date:6/23/2020)... ... 23, 2020 , ... DeCurtis Corporation, the premier provider of ... Fournier has been appointed CEO and President. Founder and former CEO, David DeCurtis, ... “DeCurtis Corporation has been on an incredible journey for the last twenty years, ...
(Date:6/23/2020)... ... 2020 , ... Nobilis Therapeutics, a biopharmaceutical company focused on ... Investigational New Drug application (IND) with the U.S. Food & Drug Administration (FDA) ... in patients with panic disorder (PD). , "Adding a PD trial to a ...
Breaking Biology Technology: